Kliniken Maria Hilf GmbH Moenchengladbach — Clinical Trial Site

41 Registered trials

17 Currently recruiting

Organisation

Kliniken Maria Hilf GmbH Moenchengladbach

Location

Moenchengladbach, Germany

Identifier

ORG-100021396

Address

Viersener Strasse 450, Windberg, 41063, Germany

Departments

-
Department of Pneumology
Hämatologie, Onkologie und Gastroenterologie
Hematology, Oncology, Gastroenterology
Hematology, Oncology, Gastroenterology Department
Innere Medizin
Innere Medizin I Hämatologie/Onkologie
Innere Medizin II, Klinik fuer Kardiologie
Innere Medizin, Hämatologie und Internistische Onkologie, Gastroenterologie, Palliativmedizin
Klinik f. Kardiologie/Intern. Intensivmedizin Studienzentrum
Klinik für Hämatologie, Onkologie und Gastroenterologie
Klinik für Kardiologie
Klinik für Kardiologie, Elektrophysiologie und Intensivmedizin
Klinik für Strahlentherapie
Klinik für Strahlentherapie und Radiologische Onkologie
Kliniken Maria Hilf GmbH Moenchengladbach
Kliniken Maria Hilf GmBH, Klinik für Hämatologie, Onkologie und Gastroenterologie
Kliniken Maria Hilf GmbH, Krankenhaus St. Franziskus
Medizinische Klinik I
Medizinische Klinik I (Klinik f. Hämatologie, Onkologie, Gastroentereologie)
NA
Strahlentherapie
Strahlentherapie und Radioonkologie

Clinical trials at this site (41)

Search interface

A phase 3 multicentre, randomized, prospective, open-label trial of Ibrutinib monotherapy versus fixed-duration Venetoclax plus Obinutuzumab… Ended

2022-500439-35-00 treatment-naive chronic lymphocytic leukemia 5 2021-02-11
Short course radiotherapy versus chemoradiotherapy, followed by consolidation chemotherapy, and selective organ preservation for MRI-defined… Ended

2024-511577-29-01 intermediate and high-risk rectal cancer 5 2020-03-13
RADIANCE Radiochemotherapy +/- Durvalumab for locally-advanced Anal Carcinoma A multicenter, randomized, phase II trial of the German Anal C… Ended

2024-513914-36-00 locally-advanced Anal Carcinoma, Anal cancer stage II a 4 2019-12-17
Efficacy of first line Bortezomib, Rituximab, Ibrutinib (B-RI) for patients with treatment naive Waldenström’s Macroglobulinemia Ended

2022-500584-12-00 Waldenström’s Macroglobulinemia 4 2019-09-11
A randomized phase III trial assessing the benefit of the addition of isatuximab to lenalidomide / bortezomib / dexamethasone (RVd) inductio… Ended

2024-513464-26-00 Multiple Myeloma 5 2018-10-18
A Clinical Phase II, multicenter, Open-label study evaluating iNduction, consolidation and maintenance treatment with Isatuximab (SAR650984)… Ended

2024-511791-32-00 Multiple Myeloma 4 2017-08-15
A large global trial to evaluate the efficacy and safety of milvexian in reducing recurrent cardiovascular events in patients after a heart … Ended

2022-501418-69-00 Acute Coronary Syndrome 5 2023-11-21
An open-label, single-arm, pilot study of Venetoclax in combination with 5 days Azacitidine in treatment-naïve subjects with acute myelogen… Ended

2022-501537-23-00 Acute myeloid leukemia 4 2023-05-16
A randomized phase III non-inferiority trial assessing lenalidomide, bortezomib and dexame-thasone induction therapy with either intravenous… Ended

2024-516300-41-00 Multiple Myeloma 5 2023-03-07
A study to learn how well the study treatment asundexian works and how safe it is compared to apixaban to prevent stroke or systemic embolis… Ended

2023-503794-38-00 Prevention of stroke or systemic embolism in atrial fib 5 2022-11-24
A Phase 3, randomized, double-blind, placebo-controlled, multicenter study of IV FDY-5301 in patients with a myocardial infarction (STEMI) Ended

2024-514372-40-00 Anterior ST-Elevation Myocardial Infarction 5 2022-04-12
A Study of Vericiguat (MK-1242) in Participants With Chronic Heart Failure With Reduced Ejection Fraction (HFrEF) Ended

2022-500881-80-00 Chronic Heart Failure With Reduced Ejection Fraction 5 2021-10-29
Thoracic Radiotherapy plus Durvalumab in Elderly and/or frail NSCLC stage III patients unfit for chemotherapy - Employing optimized (hypofra… Ended

2024-513948-28-00 unresectable stage III NSCLC (Non–small-cell lung cance 4 2020-05-08
MRD-guided treatment with pembrolizumab and azacitidine in NPM1mut AML patients with an imminent hematological relapse Ended

2024-513956-14-00 Acute myeloid leukemia 4 2019-09-16
autologous Transplantation after a Rituximab/Ibrutinib/Ara-c containing iNduction in Generalized mantle cell Lymphoma – a randomized Europea… Ended

2024-511235-10-00 Generalized mantle cell Lymphoma 5 2016-07-25
HD21 Ended

2024-518022-33-00 Advanced Stage of Hodgkin Lymphoma 5 2016-07-15
A Study to Compare the Efficacy and Safety of a Combined Regimen of Obinutuzumab and Venetoclax (GDC-0199/ABT-199) Versus Obinutuzumab and … Ended

2023-504034-22-00 Chronic Lymphocytic Leukemia (CLL) 5 2014-12-18